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Introduction: Fallopian tube, which is normally discarded in surgical procedures, has proven to be a source of
mesenchymal stem cells (MSCs) with increasing evidence. However, fallopian tube mucosa, which can be acquired via
non-invasive procedures, is a previously unknown source of MSCs. In the present study, we explored the existence of
MSCs in the human fallopian tube mucosa and also compared multipotent stem cells derived from fallopian tubes and
fallopian tube mucosa according to their biological characteristics and therapeutic potential for treatment of autologous
reproductive tract injury.
Methods: Cells isolated from human fallopian tubes and fallopian tube mucosa were expanded and characterised by flow
cytometry. The proliferative capacity of both cell types was measured by performing colony-forming unit-fibroblast and Cell
Counting Kit-8 assays. Both cell types underwent in vitro adipogenic, chondrogenic, and osteogenic differentiation. The
expression of osteocyte-, adipocyte-, and chondrocyte-related genes in the differentiated cell lineages was assessed by
reverse transcription-polymerase chain reaction. The secretion of growth factors and immunomodulatory cytokines by both
cell types were measured by enzyme-linked immunosorbent assays.
Results: We found that MSCs existed in the fallopian tube mucosa. The comparison between human fallopian tube
MSCs (hFTMSCs) and human fallopian tube mucosa MSCs (hFMMSCs) showed that hFTMSCs had a stronger
proliferative capacity and shorter duplication time than hFMMSCs. Both cell types could be differentiated into
adipocytes, osteoblasts, or chondrocytes in vitro. Real-time polymerase chain reaction analysis demonstrated that
hFTMSCs displayed increased expression of osteogenic-specific genes compared with hFMMSCs, but the two types of
cells showed no significant increase in the mRNA expression of adipogenic-specific or chondrogenic-specific genes.
hFMMSCs and hFTMSCs robustly produced a variety of growth factors and immunomodulatory cytokines.
Conclusions: Human fallopian tube mucosa is a novel source of multipotent cells. hFMMSCs demonstrated stronger
proliferative capacity and superior secretion of growth factors and immunomodulatory cytokines than hFTMSCs, making
the former a better source of stem cells for the treatment of autologous reproductive tract injury. Compared with fallopian
tube, fallopian tube mucosa has more wide-ranging applications and can be used to carry out autologous transplantation.Introduction
Mesenchymal stem cells (MSCs) are increasingly found
within different post-natal tissues. In 2009, Jazedje et al.
showed for the first time that human fallopian tubes are a
rich additional source of MSCs and these cells were* Correspondence: one_army@sina.com
1Department for Gynaecology and Obstetrics, Navy General Hospital, PLA,
Fuchengmen Road, No.6, Beijing 100048, China
Full list of author information is available at the end of the article
© 2015 Wang et al. This is an Open Access art
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/designated as human tube MSCs (htMSCs) [1]. The studies
were of great interest to researchers and clinicians inter-
ested in reproduction because they initiated the use of au-
tologous multipotent stem cells derived from human
fallopian tubes as a novel source of stem cells for regenera-
tive medicine and they highlighted the usefulness of a ma-
terial that is typically discarded after surgery. Although
human fallopian tubes are a promising source of autologousicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Sources of fallopian tube and mucosa samples
Patient Age, years Left side Right side
1 36 Fallopian tube Fallopian tube mucosa
2 37 Fallopian tube Fallopian tube mucosa
3 43 Fallopian tube Fallopian tube mucosa
4 48 Fallopian tube Fallopian tube mucosa
5 53 Fallopian tube Fallopian tube mucosa
6 55 Fallopian tube Fallopian tube mucosa
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through a surgical process.
The human fallopian tube is a tubular and seromuscular
organ composed of tunica mucosa and two intertwined
smooth muscle layers covered by serosa. Fallopian tube
mucosa is divided into epithelial lining and the lamina
propria [2, 3]. The epithelial lining is uniquely equipped
with ciliated and secretory cell types that facilitate ovum
pick-up and transport of spermatozoa and ova in opposite
directions and that are where fertilization normally takes
place. Peg cells are described as stem-like cells and are
concentrated on the fimbriated distal end of the fallopian
tube [4]. The lamina propria is a layer of loose connective
tissue that lies beneath the epithelium and is embedded
with a currently unidentified, dispersed network of
fibroblast-mesenchymal cells. The fallopian tubes are lo-
cated between the area where ovulation occurs and the
uterus where the zygote is implanted and they act as brid-
ges for sperm and egg transport [5]. The fallopian tube
mucosa undergoes periodic changes during the menstrual
cycle that result in damage and regeneration [6]. In
addition, owing to cyclic ovulatory damage, the fallopian
tube must exhibit regenerative activity to rapidly re-
establish its normal important reproductive function [7].
The fallopian tube mucosa is similar to endometrium be-
cause of its periodic shedding and regeneration during the
menstrual cycle throughout a woman’s reproductive life.
Fallopian tube mucosa shares the same embryological ori-
gin as the endometrium derived from the mucosal lining
of the fused mesodermal (paramesonephric) tubes (the
Mullerian ducts), which are both dynamic tissues [8]. Pre-
vious studies have reported the presence of mesenchymal
multipotent cells in many human tissue mucosae, such as
endometrium, oral mucosa, intestinal mucosa, ethmoid
sinus mucosa, and olfactory mucosa; however, no studies
have shown that multipotent stem cells are located in the
fallopian tube mucosa [9–14]. Endometrial wound healing
involves substantial tissue destruction and subsequent re-
pair and remodelling. Stem cells within the deeper basal
layer in the human endometrium that are capable of produ-
cing progenitor cells that further differentiate into epithelial,
stromal, and endothelial cells as well as growth factors and
inflammatory cells play important roles in reconstructing
the endometrium [15]. Therefore, we suggested that, simi-
lar to the endometrium, multipotent stem cells exist in the
fallopian tube mucosa and that fallopian tube mucosa is a
novel source of autologous multipotent stem cells. In our
opinion, fallopian tube mucosa, which can be obtained by
biopsy, is a novel tool that can be used in regenerative
medicine. We speculated that multipotent stem cells might
exist in the lamina propria of the fallopian tube mucosa.
To identify the stem cells within the fallopian tube mucosa
and to search for new and alternative sources of MSCs,
we identified, isolated, and expanded fallopian tubemucosa multipotent stem cells. Herein, we compared
multipotent stem cells derived from fallopian tubes and
fallopian tube mucosa according to their biological char
acteristics and therapeutic potential and assessed their
potential for treatment of autologous reproductive tract
injury.
Methods
Tissue preparation and cell isolation
Fallopian tube preparation
Human fallopian tubes (n = 12) were obtained from hys-
terectomy or tubal ligation/resection samples collected
from 35- to 55-year-old fertile women who had not
undergone exogenous hormonal treatment for at least 3
months prior to surgery and who had benign disease
that did not affect the fallopian tubes. Each patient had
undergone bilateral salpingectomy. Informed consent
was obtained from each patient, and the experiment
was approved by the medical ethics committee of Navy
General Hospital.
Fallopian tube mucosa preparation
The fallopian tube samples (n = 6) and the mucosa sam-
ples (n = 6) derived from the same patients. All of the
fallopian tube samples that were acquired from the left
side of the patients still contain the mucosa, and the
mucosa samples derived from the right-side fallopian
tube of the same patient are listed at Table 1. According
to a previously published protocol for isolating human
amniotic stem cells, human fallopian tube mucosa was
obtained from fallopian tubes that would normally have
been discarded after tubal ligation/resection [16]. Cell
culture media and reagents were purchased from Gibco
(Invitrogen, Carlsbad, CA, USA). An entire fallopian
tube was placed on a sterile field and longitudinally dis-
sected to expose the fallopian tube mucosa. Then
calcium- and magnesium-free Hanks’ balanced salt solu-
tion (CMF-HBSS) was added to the mucosa; thereafter,
the mucosa was gently massaged to remove blood clots
and subsequently peeled using forceps. Each sample was
immediately collected in HEPES-buffered Dulbecco’s
modified Eagle’s medium/Hams F-12 (DMEM/F-12),
maintained at 4 °C, and processed within 24 hours. In-
formed consent was also obtained from each patient,
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Cell isolation
All samples were repeatedly washed in CMF-HBSS until
all blood cells were removed. The samples were then
finely sliced into small pieces, placed inside in a 50-ml
Falcon tube, and incubated in 10 ml of trypsin in a re-
ciprocating water bath at 37 °C for 30 minutes. Subse-
quently, the samples were washed once with 10 ml of
DMEM/F-12 supplemented with 10 % fetal bovine
serum (FBS) and pelleted by centrifugation at 800×g/mi-
nute for 8 minutes at room temperature; thereafter, the
supernatant was removed with a sterile Pasteur pipette
and washed twice with 10 ml of (HBSS) as previously
described by Jazedje et al. [1]. After trypsin digestion,
further digestion was performed by using 0.1 % collage-
nase I in a reciprocating 37 °C water bath overnight, and
the isolated cells were centrifuged at 400×g for 10 mi-
nutes and subsequently washed twice with 10 ml of
HBSS. The cell pellets were resuspended in DMEM/
F-12 (5 ml) supplemented with 10 % FBS, 100 IU/ml
penicillin, and 100 IU/ml streptomycin in plastic flasks
(25 cm2) coated with gluten and maintained in a hu-
midified atmosphere of 5 % CO2 in air at 37 °C. The cul-
ture medium used for expansion was initially changed
every 72 hours and routinely replaced twice a week
thereafter. After each passage, the cells were frozen.
Flow cytometry analysis
For cell surface characterisation, the cells were harvested
by using 0.25 % trypsin-EDTA and resuspended in HBSS
at a concentration of 1.0×106 cells/ml. The cell suspen-
sions (100 μl) were resuspended in a fluorescence-
activated cell sorting tube and stained to evaluate the ex-
pression of a variety of markers specific to MSC,
hematopoietic, and endothelial lineages; these markers
included CD13-FITC, CD29-APC, CD44-PE, CD90-
FITC, CD14-APC, CD19-APC, CD34-PE, CD45-FITC,
CD73-PE, CD105-PercP CD166-PE, HLA-DR-APC, and
HLA-ABC-FITC. Mouse lgG1-FITC, mouse lgG1-APC,
mouse lgG1-PE, and mouse lgG1-PercP were used as
negative controls. The cells were pelleted by centrifuga-
tion at 800×g/minute or 5 minutes at room temperature,
resuspended in 30 μl of sheath reagent, and mixed with
a vortex oscillator. Immunofluorescence antibodies and
100 μl of cell supernatant were added to three Falcon
tubes, mixed with a vortex oscillator, and kept in a dark
place at room temperature for 20 minutes. One millilitre
of sheath reagent was added into each tube, and the cell
solution was mixed with a vortex oscillator, centrifuged at
800×g/minute for 5 minutes at room temperature, resus-
pended in 200 μl of sheath solution, maintained at 4 °C in
the dark, and tested within 3 hours. All flow cytometryanalyses were performed by using Cell Quest software
version 3.1 (BD Biosciences, Franklin Lakes, NJ, USA).
Characteristics of cell proliferation and population
doubling time
Cell growth kinetics were measured every day for up to
9 days by using a cell counting kit (Bi-Yun-Tian, Peking,
China). The fifth passages of human fallopian tube
MSCs (hFTMSCs) and human fallopian tube mucosa
MSCs (hFMMSCs) were seeded at 1×103 cells per well in
96-well plates containing DMEM/F-12. Over the following
9 days, 10 μl of Cell Counting Kit-8 (CCK-8) reagent (Beyo-
time Institute of Biotechnology, Haimen City, China) was
added into six wells each day, and the cells were incubated
for 4 hours in a CO2 incubator until the medium turned
yellow. Then cell growth kinetics were measured. The ab-
sorbance was determined at 450 and 630 nm by using an
auto-microplate reader. With the proliferation curve, the
population doubling (PD) time in the logarithmic phase
was calculated by using the formula logN/log2, where N is
the absorbance of the terminal portion of the logarithmic
phase, the cumulative PD level is the sum of the PDs, and
the PD rate is the PD divided by time in culture.
Colony-forming unit-fibroblast assay
hFTMSCs and hFMMSCs were plated at a density of
1,000 cells per well in six-well plates and allowed to
grow for 15 days. The cultures were terminated and
stained with crystal violet for colony visualization. A col-
ony was defined as a group of cells (>40). The colonies
were counted manually under an inverted microscope.
Differentiation assays
Adipogenic differentiation
Passage 5-cultured MSCs were plated at a density of
3×104 cells per well in 24 wells, subjected to adipogenic
differentiation induction protocols. Adipogenic differen-
tiation was induced in medium containing DMEM sup-
plemented with 10 % FBS, 100 U/ml penicillin, 100 μg/
ml streptomycin, 12 mM L-glutamine, 10 μM insulin,
200 μM indomethacin, 1 μM dexamethasone, and 0.5 mM
3-isobutyl-1-methylxanthine (IBMX) (Sigma-Aldrich, St.
Louis, MO, USA). The cells were cultured for 3 weeks,
and the medium was changed twice a week. DMEM sup-
plemented with 10 % FBS was used as the control. Accu-
mulation of lipids in these vacuoles was assayed
histologically by Oil Red O staining. Briefly, the intracellu-
lar accumulation of lipid-rich vacuoles was monitored by
staining with 0.3 % Oil Red O solution. First, the cells
were fixed in 10 % formalin for 10 minutes; next, they
were washed with HBSS and stained with 0.3 % Oil Red O
solution for 10 minutes at room temperature. Intracellular
lipid-rich vacuoles were stained as red foci.
Wang et al. Stem Cell Research & Therapy  (2015) 6:98 Page 4 of 13Osteogenic differentiation
MSCs at passage 5 (3×104 cells) were cultured in 24-well
plates containing proliferation medium and allowed to
attain 70 % to 80 % confluency. In brief, osteogenic dif-
ferentiation was induced in medium containing low-
glucose DMEM, 10 % FBS, 100 μM ascorbic-2-phosphate,
10 mM b-glycerophosphate, and 100 nM dexamethasone
(all from Sigma-Aldrich, Gillingham, UK). The cells were
maintained in differentiating medium for 28 days, and
medium was changed twice a week. At the end of the ex-
periment, the differentiated cells were washed twice with
phosphate-buffered saline (PBS) and fixed with 10 % for-
malin for 10 minutes at room temperature. The cells were
then washed thoroughly with PBS and stained with 2 %
Alizarin Red S solution (pH = 4 to 4.1), followed by incu-
bation with 0.5 % NH4OH for 2 to 5 minutes. The minera-
lised matrix was identified by the presence of red foci in
the stained specimens. The cells were stained with 2 %
Alizarin Red S (Sigma-Aldrich, UK) solution to evaluate
the mineralised matrix, and the number and size of miner-
alising nodules were maximised.
Chondrogenic differentiation
To induce chondrogenic differentiation, MSCs at pas-
sage 5 were plated in 24-well culture plates at a concen-
tration of 1×104 cells/ml and allowed to grow until 70 %
to 80 % confluency. The proliferation medium was re-
placed with chondrogenic medium consisting of high-
glucose DMEM supplemented with 0.1 μM dexa-
methasone, 10 ng/ml transforming growth factor-beta
1 (TGF-β1), 50 μg/ml ascorbic acid and 50 mg/ml
insulin-transferrinselenium (ITS) + premix (Becton
Dickinson, Franklin Lakes, NJ, USA), 6.25 μg/ml insulin,
6.25 μg/ml transferrin, 6.25 ng/ml selenious acid, and 10
% FBS at 37 °C for 3 weeks. Medium changes were carried
out twice a week, and chondrogenesis was assessed at
weekly intervals. To determine the presence of glycosami-
noglycans within the extracellular matrix, the cells were
stained with toluidine blue (Sigma-Aldrich). Briefly, the
differentiated cells were fixed with 10 % formalin for 10








Type II collagen 5′-CTGGTATTGCTGGCTTCAA
Aggrecan 5′-CTGCTTCCGAGGCATTTCARNA preparation and quantitative reverse
transcription-polymerase chain reaction analysis
Reverse transcription-polymerase chain reaction (RT-PCR)
analysis was performed to assess the expression of
osteocyte-, adipocyte-, and chondrocyte-related genes in
the differentiated cell lineages. Adiponectin, peroxisome
proliferator-activated receptor gamma 2 (PPAR-γ2), and
adipocyte protein 2 (AP2) were used to evaluate the poten-
tial for adipogenic differentiation. Osteocalcin, osteopontin,
and alkaline phosphatase were related to the osteogenic po-
tential. The chondrogenic potential was assessed on the
basis of the expression of type II collagen and aggrecan.
Total RNA was extracted by using an RNA Extraction Kit
(Bio-Rad Laboratories, Inc., 313 Hercules, CA, USA) in ac-
cordance with the instructions of the manufacturer. Before
reverse transcription, the extracted RNA samples were
treated with RNase-free DNaseI to ensure that the ex-
tracted RNA used to synthesize cDNA was free of DNA
contamination. RT-PCR analysis was performed to assess
the expression of adipocyte-, osteocyte-, and chondrocyte-
related genes in the differentiated cell lineages. The
extracted RNA samples were subjected to the reverse-
transcription reaction by using 1 mg of extracted RNA in
accordance with the instructions provided with the RNA-
to-cDNA Kit (Bio-Rad Laboratories, Inc., 313 Hercules,
CA, USA). The final quantitative RT-PCR contained com-
plementary DNA template, iTaq SYBR Green Supermix
with ROX (Bio-Rad Laboratories, Inc., Hercules, CA, USA),
and gene-specific primers (Table 2). The following PCR
conditions were used: 50 °C for 2 minutes and 95 °C for 10
minutes, followed by 40 cycles of 30 seconds at 95 °C, 45
seconds at 60 °C, and 30 seconds at 72 °C. Beta actin was
used as an internal control. The cycle threshold values of
beta actin and other specific genes were calculated after the
PCR. The normalised fold expression was obtained by using
the 2−△△CT method. The results were expressed as the nor-
malised fold expression for each gene.
Enzyme-linked immunosorbent assay of growth factors
To evaluate the potency of the growth factor production,
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3 days. The cell supernatants were collected to detect
secreted vascular endothelial growth factor (VEGF),
epidermal growth factor (EGF), basic fibroblast growth
factor (bFGF), hepatocyte growth factor (HGF), and
granulocyte-macrophage colony-stimulating factor (GM-
CSF) by using human enzyme-linked immunosorbent
assay (ELISA) kits (R&D Systems Inc., Minneapolis,
MN, USA) in accordance with the instructions of the
manufacturer.
Enzyme-linked immunosorbent assay of
immunomodulatory cytokines
To detect the secretion of cytokines related to immuno-
modulation, the cells were processed as described earlier.
The levels of interleukin-2 (IL-2), IL-4, IL-6, IL-10, TNF-
α, TNF-β, and interferon-gamma (IFN-γ) were measured
by using human ELISA kits (R&D Systems Inc.) in accord-
ance with the instructions of the manufacturer.
Statistical analysis
Except where otherwise indicated, all of the experiments
were repeated three times. Two-sample Student’s t test
and analysis-of-variance tests were used for statistical
analyses, and P <0.05 was considered significant. The
data were expressed as the mean ± standard deviation of
the mean. Statistical analysis of the quantitative RT-PCR
data and group comparisons were performed by using
the pairwise fixed reallocation randomisation test with
the Relative Expression Software Tool (REST 2008). A P
value of 0.05 was considered statistically significant.
Results
Characterisation of cell phenotypes
Cells isolated from human fallopian tube were morpho-
logically distinguishable from those derived from fallo-
pian tube mucosa. Compared with cells isolated fromFig. 1 Morphology of human fallopian tube mesenchymal stem cells (MSC
MSCs isolated from human fallopian tube after 12 days of culturing. b The
days of culturing. Scale bars, 100 μmfallopian tube mucosa, which exhibited spindle-shaped
or fibroblast-like morphology, cells isolated from fallo-
pian tubes were larger and had a round, flat shape and
nuclear hyperchromatism. The majority of both isolated
cell types were adherent to flasks after 24 hours of culti-
vation. Ten to fourteen and 5 to 7 days were required
for the primary cells isolated from fallopian tubes and
fallopian tube mucosa to reach confluency, respectively,
and the adherent cells formed homogenous cell layers
with a whirlpool phenotype (Fig. 1a, b). Flow cytometric
analyses were performed to analyse the cells isolated
from fallopian tubes and fallopian tube mucosa. The ex-
pression profiles of the cells isolated from human fallopian
tubes and fallopian tube mucosa and stained with various
stem cell markers are presented in Fig. 2. The flow cyto-
metric analyses revealed that hFTMSCs and hFMMSCs
were positive for mesenchymal markers (CD90, CD73,
and CD105) and cell adhesion molecules (CD166 and
HLA-ABC) and were negative for hematopoietic lineage
markers (CD34, CD45, CD14, HLA-DR, and CD19).
Compared with hFMMSCs, hFTMSCs exhibited higher
expression of CD44 and CD13.
Mesenchymal stem cell expansion and population
doubling times
hFTMSCs began to proliferate immediately after being
plated, but the hFMMSCs first underwent a latent phase
(the first day). Subsequently, both cell types showed ac-
celerated growth during days 2 to 5 (logarithmic phase)
and reached a plateau within 5 to 8 days after culture
(Fig. 3a). From the growth curve, we determined that
the PD times of fifth-passage hFTMSCs and hFMMSCs
in the logarithmic phase were 37.04±3.59 hours and
23.48±0.86 hours, respectively, and a significant differ-
ence was found between the values for hFTMSCs and
hFMMSCs (P <0.05) (Fig. 3b). hFMMSCs have a shorter
PD time and greater proliferative capacity than hFTMSCs.s) and human fallopian tube mucosa MSCs. a The morphology of the
morphology of the MSCs obtained from fallopian tube mucosa after 7
Fig. 2 Flow cytometry analysis of cells harvested from human fallopian tube and human fallopian tube mucosa. Mesenchymal stem cells
were positive for mesenchymal markers CD90, CD73, and CD105 and cell adhesion molecules CD166 and HLA-ABC and were negative for
hematopoietic markers CD34, CD14, CD19, HLA-DR, and CD45. FMMSC, fallopian tube mucosa mesenchymal stem cell; FTMSC, fallopian tube
mesenchymal stem cell
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Cells isolated from fallopian tubes and fallopian tube
mucosa were able to grow into colonies. The clonogenic
abilities of hFMMSCs and hFTMSCs were determined
by colony-forming unit-fibroblast (CFU-F) assays. When
these cells were grown at low numbers (1,000 cells/cm2)
to determine colony-forming units (CFUs), more col-
onies were formed from hFMMSCs (129.33±4.04) than
from hFTMSCs (129.33±4.04) (71±3.61) at passage 5
(Fig. 4).Fig. 3 The comparison of proliferative capacity between human fallopian t
mucosa mesenchymal stem cells (hFMMSCs). a Comparative analysis of cel
analysis of duplication time between hFTMSCs and hFMMSCs. OD, optical dCell differentiation assays
Adipogenic differentiation
The potential for adipogenic differentiation was evalu-
ated by using Oil Red O, which stains lipid-rich vacu-
oles. hFTMSCs and hFMMSCs demonstrated adipogenic
potential; however, hFTMSCs displayed similar lipid
droplets in the cytoplasm with hFMMSCs (Fig. 5a). The
adipogenic potential was quantified by quantitative PCR.
Adiponectin, PPAR-γ2, and AP2, which are specific adi-
pogenic differentiation factors, were measured to analyseube mesenchymal stem cells (hFTMSCs) and human fallopian tube
l proliferative curve between hFTMSCs and hFMMSCs. b Comparative
ensity
Fig. 4 The colony-forming unit-fibroblast (CFU-F) assay of human fallopian tube mesenchymal stem cells (hFTMSCs) and human fallopian tube
mucosa mesenchymal stem cells (hFMMSCs). a The cells were plated at a density of 1,000 cells per well and cultured for 15 days in six-well plates.
b The cells were stained with crystal violet dye (0.1 %), and cell colonies with more than 40 cells were counted (×100). c The cells were plated at
a density of 1,000 per well, and the percentage plating efficiency ([number of colonies counted/number of cells plated] ×100 %) of hFMMSCs
was higher compared with hFTMSCs
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no significant difference in the expression levels of these
factors, and this was in accordance with the qualitative
results by Oil Red O staining (Fig. 5b).
Osteogenic differentiation
The mineralised matrix was evaluated by 2 % Alizarin
Red staining to analyse the osteogenic potential. Both
cell types displayed positive staining after 24 days of the
pro-osteogenic protocol. No difference was observed be-
tween the matrices of two cell types after staining
(Fig. 6a). Osteogenic-specific gene expression was mea-
sured to quantify the osteogenesis. Compared with
hFMMSCs, hFTMSCs displayed a significantly higher
expression of the three genes (P <0.05) (Fig. 6b).
Chondrogenic differentiation
The chondrogenic potential was estimated by staining
with Alcian blue, which demonstrated that both cell
types produced extracellular matrix composed of glycos-
aminoglycans and mucopolysaccharides (Fig. 7a). To
quantify the chondrogenesis, we performed RT-PCR,
which showed a significant increase in the mRNA ex-
pression of aggrecan and collagen type II genes in MSCs
treated with chondrogenic differentiation medium com-
pared with untreated MSCs. Additionally, compared
with hFMMSCs, hFTMSCs displayed no significantdifference in expression of aggrecan and collagen type II
(Fig. 7b).
In vitro secretion of growth factors
Increasing evidence supports the generalisation that cell
therapy boosts tissue repair function largely via para-
crine mechanisms [26]. The ability of cells isolated from
human fallopian tubes and fallopian tube mucosa to se-
crete large amounts of all growth factors has not been
reported. The production of five types of growth factors
(VEGF, EGF, bFGF, HGF, and GM-CSF) by hFTMSCs
and hFMMSCs was measured and compared. hFMMSCs
produced more EGF, bFGF, and GM-CSF than hFTMSCs
(P <0.05). However, the secretion of HGF and VEGF by
hFTMSCs was increased (P <0.05) (Fig. 8a).
Detection of immunomodulatory cytokines
A series of immunomodulatory factors, including cyto-
kines IL-2, IL-4, IL-6, IL-10, TNF-α, TNF-β, and IFN-γ,
were measured to estimate the immunomodulatory ef-
fects of cultured MSCs on the human immune system
and implantation. Cells isolated from human fallopian
tube mucosa secreted more IL-4 and TNF-β than cells
isolated from fallopian tubes, and hFMMSCs produced
lower amounts of IFN-γ than hFTMSCs (P <0.05). No
significant difference in the secretion of IL-6 and TNF-α
was found between hFTMSCs and hFMMSCs. Owing to
Fig. 5 Assessment of adipogenic induction. Both types of mesenchymal stem cells (MSCs) were treated with induction medium for 21 days, and
differentiation potential was assessed with quantitative reverse transcription-polymerase chain reaction. a Adipogenic differentiation of human
fallopian tube MSCs (hFTMSCs) and human fallopian tube mucosa MSCs (hFMMSCs) was stained by Oil Red O (×400). b Gene expression profile
of induced MSCs. No significant differences were observed in mRNA levels of peroxisome proliferator-activated receptor gamma (PPAR-γ2),
adiponectin, and adipocyte protein 2 (AP2) between hFTMSCs and hFMMSCs (P >0.05)
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detected (Fig. 8b).
Discussion
Bone marrow-derived MSCs (BM-MSCs) are still recog-
nized as stem cell banks in the area of regenerative
medicine. However, more and more tissues are found to
host MSCs, and a search for alternative sources of MSCs
to replace BM-MSCs is an important aspect to consider
for regenerative medicine applications [17–21]. Fallopian
tubes, which are normally discarded in surgical proce-
dures, are a source of MSCs for regenerative medicine
and can be used to carry out autologous transplantation,
but there are certain limitations: (1) The supplication is
limited because only a few patients have the request for
tubal resection, and (2) if fallopian tube is used for au-
tologous transplantation, its scope of application will be
limited. Not everyone wants to remove their own fallo-
pian tube tissue if unnecessary.
In 2009, Jazedje et al. showed for the first time that
human fallopian tube is a rich additional source of MSCs
and these cells were designated as htMSCs [1]. In 2012,
Jazedje et al. reinforced the idea that the autologoushFTMSCs transplanted into non-immunosuppressed
rats can successfully enhance bone regeneration in vivo
and have potential use for treatment of osteoporosis and
bone reconstruction or regeneration [22]. In 2013, Indu-
mathi et al. confirmed again the existence of hFTMSCs.
They also made a comparison of hFTMSCs and BM-
MSCs in terms of their biological characteristics and
found that hFTMSCs could replace the BM-MSCs and
be additional stem cell sources for regenerative medicine
[8]. We found that, in the previous study, the human fal-
lopian tubes were obtained from hysterectomy or tubal
ligation/resection and that the whole layers of fallopian
tube are digested to isolate the MSCs. The fallopian tube
can be divided into three layers from inside out: tunica
mucosa and two intertwined smooth muscle layers cov-
ered by serosa. Although our study focused on an in-
novative method, we try to strip the fallopian tube
mucosa absolutely out of the whole fallopian tube tissue
and then have a digestion of the stripped fallopian tube
mucosa to isolate the MSCs, and we suggest that this
cell source is suitable for regenerative medicine and has
a broader application than hFTMSCs. Fallopian tube
mucosa can be obtained by the salpingo-scope, which is
Fig. 6 Osteogenic potential of mesenchymal stem cells (MSCs). Both types of MSCs were treated with induction medium for 21 days, and
differentiation potential was assessed with quantitative reverse transcription-polymerase chain reaction (RT-PCR). a Differences in matrix mineralisation
were seen between human fallopian tube MSCs (hFTMSCs) and human fallopian tube mucosa MSCs (hFMMSCs) by staining with 2 % Alizarin Red
(×100). b Quantitative RT-PCR shows that alkaline phosphatase, osteocalcin, and osteonectin levels were significantly higher in hFTMSCs compared
with hFMMSCs (P <0.05).
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vaginal route is the least invasive and most economical
route and should be the first choice to obtain the
hFMMSCs. Although our study did not get the fallopian
tube mucosa through the salpingo-scope, we will take it
into consideration in our further study.
In this study, we performed a head-to-head compari-
son of the two kinds of stem cell types for autologous
transplantation by assessing multiple in vitro parameters.
hFMMSCs are smaller and thinner than hFTMSCs and
can be mixed with other unidentified cells derived from
the seromuscular layer. Thus, our novel isolation of
purified multipotent cells from fallopian tube mucosa is
meaningful. Our study demonstrated that hFMMSCs have
a more powerful proliferative capacity than hFTMSCs.
hFTMSCs displayed superiority over hFMMSCs in bone
formation, but the two types of cells showed no significant
increase in the mRNA expression of chondrogenic- and
adipogenic-specific genes. hFMMSCs and hFTMSCs ro-
bustly produced a variety of growth factors, including
bFGF, EGF, GM-CSF, HGF, and VEGF. Importantly,
hFMMSCs secreted more bFGF, EGF, and GM-CSF thanhFTMSCs, all of which are involved in the re-
epithelialisation.
To the best of our knowledge, this is the first report
on the isolation of cells from fallopian tube mucosa, and
these cells adhered to the minimum criteria proposed by
the Mesenchymal and Tissue Stem Cell Committee of
the International Society for Cellular Therapy for defin-
ing human MSCs. These criteria consist of the following
three points: (1) MSCs must be plastic-adherent; (2) they
must express CD105, CD73, and CD90 and lack expres-
sion of CD45, CD34, CD14 or CD11b, CD79a, CD19,
and HLA-DR surface molecules; and (3) they must be
able to differentiate into osteoblasts, adipocytes, and
chondroblasts in vitro [24]. Our study found that
hFMMSCs have a more powerful proliferative capacity
than hFTMSCs and demonstrated its great application
value. The required cell number for cell therapy is
1×106/kg; for an adult weighing 50 kg, the total cell
number required for therapy is 5×107. So achieving a
sufficient amount of cells in a short period of time is
important in order to achieve the best treatment time,
especially for autologous transplantation. MSCs with a
Fig. 7 Chondrogenic potential of mesenchymal stem cells (MSCs). Both types of MSCs were treated with induction medium for 21 days, and
differentiation potential was assessed with quantitative reverse transcription-polymerase chain reaction (RT-PCR). a Abundance of glycosaminoglycans
and mucopolysaccharides within the extracellular matrix was demonstrated by the positive Alcian blue staining of induced MSC culture. Both types of
MSCs showed chondrogenic induction 21 days after induction (×200). b mRNA expressions of aggrecan and collagen type II which were performed
by quantitative RT-PCR showed that equivalent mRNA level was observed for aggrecan and collagen between both tissue types (P >0.05). hFMMSC,
human fallopian tube mucosa mesenchymal stem cell; hFTMSC, human fallopian tube mesenchymal stem cell; n.s., not significant
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time. Thus, we can achieve a standard amount of cells in
an extraordinarily short time.
hFMMSCs can be a supplement of autologous trans-
plantation source and broaden the application scope, es-
pecially for the treatment of autologous reproductive
tract injury. Fallopian tube mucosa may the best source
of material for endometrial reconstruction and restor-
ation of reproductive function because of its ability to
mediate blastocyst adhesion to the fallopian epithelium
leading to pregnancy [25]. Furthermore, fallopian tube
mucosa may be a good source of material because of its
similarity to the surrounding tissue. The fallopian tube
and uterus share the same embryological origin and both
are dynamic tissues [6, 8].
There is evidence that the mechanisms involved in the
therapeutic properties of tubal mucosa include not only
the ability of the tubal mucosa multipotent stem cells to
differentiate into endometrium to replace the injured
cells but also their secretion of factors that promote
endometrium repair in a paracrine manner. These fac-
tors are divided into six categories: immunomodulation,
anti-apoptosis, angiogenesis, support of the growth anddifferentiation of local stem and progenitor cells, anti-
scarring, and chemoattraction to promote tissue repair
[26]. MSCs also attenuate the pathological remodeling,
including scar formation, of many tissues, such as the
heart, airways, and skin [27]. Our study showed that
hFMMSCs and hFTMSCs robustly produced a variety of
growth factors, including bFGF, EGF, GM-CSF, HGF,
and VEGF. Importantly, hFMMSCs secreted more bFGF,
EGF, and GM-CSF than hFTMSCs. EGF and bFGF were
reported to have significant promoting effects on the mi-
gration and proliferation of functional cells in wound
healing. EGF has been found to play a critical role in the
wound healing process [28–30]. Based on this, we ob-
served that hFMMSCs demonstrated their superiority to
hFTMSCs in re-epithelialisation. The secretion of immu-
nomodulatory factors, including the cytokines IL-4, IL-6,
TNF-α, TNF-β, and IFN-γ, by both cell types demon-
strates the immunomodulatory function of the cells.
Compared with hFTMSCs, hFMMSCs secrete more of
the anti-inflammatory cytokine IL-4 and less of the pro-
inflammatory cytokine IFN-γ, and this indicates that
hFMMSCs have a stronger anti-inflammatory role, mak-
ing them particularly beneficial in chronic wound
Fig. 8 Comparison of in vitro production of growth factors and immunomodulatory cytokines from cultured cells. a Concentrations of vascular
endothelial growth factor (VEGF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and
granulocyte-macrophage colony-stimulating factor (GM-CSF) measured by using enzyme-linked immunoadsorbent assay (n = 3) are depicted.
b Concentrations of interleukin-4 (IL-4), IL-6, tumor necrosis factor-alpha (TNF-α), TNF-β, and interferon-gamma (IFN-γ) measured by using
enzyme-linked immunoadsorbent assay (n = 3) are depicted. hFMMSC, human fallopian tube mucosa mesenchymal stem cell; hFTMSC, human
fallopian tube mesenchymal stem cell
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inflammatory state into the next stage of healing. There-
fore, hFMMSCs are a better stem cell source than
hFTMSCs for the treatment of autologous reproductivetract injury mainly because of their rapid cell expansion,
which is the decisive factor for the assessment of the
therapeutic potential of autologous therapies. hFMMSCs
can be produced in ample numbers soon after injury. The
Wang et al. Stem Cell Research & Therapy  (2015) 6:98 Page 12 of 13cells should be available and should be acquired in ample
numbers immediately after injury. In addition, their
powerful secretion of growth factors, which is crucial for
re-epithelialisation, is beneficial.
These results inspired a search for autologous multi-
potent stem cells derived from human fallopian tube
mucosa. In summary, the mucosa of all tissues will be
the best source of multipotent stem cells because the
multipotent stem cells in the complete tissue mucosa
are superior to those of the whole tissue. Mucosa, which
forms the lining of many body cavities such as the di-
gestive, respiratory, and reproductive tracts, acts as a
barrier to the outside environment and has powerful re-
generative ability. Tissue mucosa can be uneventfully
harvested from patients in a minimally invasive, virtually
painless manner with low morbidity. All human tissue
mucosa can be obtained by biopsy rather than through
surgical procedures. Thus, we suggest that MSCs iso-
lated from tissue mucosa are a novel, promising, and
abundant source of MSCs that shows superior potential
for cell therapy because of the straightforward, easy, and
minimally invasive collection; high proliferative capacity;
and immunomodulation and tropism for the healing of
injuries. Furthermore, autologous transplantation can
overcome the traditional hazards associated with allogenic
transplantation. So we proposed that MSCs isolated au-
tologous mucosa may be best source of MSCs. Therefore,
we propose also that autologous mucosa, which has the
regenerative capacity to recover its integrity after biopsy,
may be the best source of MSCs.
All in all, we focus especially on the comparison of
stem cells acquired from two different methods. Fallo-
pian tube mucosa can be acquired by salpingo-scope,
and we have demonstrated the existence of MSCs in
our study. Although in our experiments we did not
use the tool of salpingo-scope to get fallopian tube
mucosa, we at least show that fallopian tube mucosa is
a better stem cell source than the whole fallopian tube
in many ways. So we proposed to obtain fallopian tube
mucosa by salpingo-scope to replace tubal resection.
We also successfully isolated MSCs from the fallopian
tube, but tubal resection is more invasive than
salpingo-scope and is associated with more discomfort
for the patient. In addition, we found that hFTMSCs
are inferior to hFMMSCs according to their biological
characteristics and therapeutic potential. We con-
cluded that regardless of the acquisition method and
their biological characteristics and therapeutic poten-
tial, the fallopian tube mucosa is a better MSC source
than the fallopian tube.
Conclusions
In our study, we make a comparison of hFTMSCs with
hFTMSCs to find a better stem cell source to repairhuman reproductive tract. Although these data showed
that hFTMSCs demonstrated stronger proliferative cap-
acity and superior secretion of growth factors and im-
munomodulatory cytokines and we also found that
multipotent stem cells derived from tissue mucosa have
advantages over the whole tissue because of their min-
imally invasive collection method, high proliferative cap-
acity, immunomodulation and tropism for the healing of
injuries as well as autologous transplantation can also be
realised by using tissue mucosa. Fallopian tube mucosa
is a convenient and readily available source of stem cells,
and the harvest procedure is less invasive than tubal re-
section and is associated with little discomfort for the
patient. Fallopian tube mucosa has wide-ranging applica-
tions and can be used to carry out autologous transplant-
ation. hFMMSCs demonstrated an obvious superiority
in clinical applications, and especially for the repair of
autologous reproductive tract injury, fallopian tube mu-
cosa performed the potential application.Abbreviations
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